These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 7636540)

  • 41. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
    Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
    N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.
    Tulpule A; Sherrod A; Dharmapala D; Young LL; Espina BM; Sanchez MN; Gill PS; Levine AM
    Leuk Res; 2002 Feb; 26(2):121-7. PubMed ID: 11755462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Lennert K; Wellens W; Schmidt M; Gassel WD; Kolb T; Hässler R
    Br J Cancer; 1989 Jul; 60(1):79-82. PubMed ID: 2679846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
    Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
    J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
    Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
    J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
    Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
    Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
    Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
    Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
    J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activity of infusional etoposide, vincristine, and doxorubicin with bolus cyclophosphamide (EPOCH) in relapsed Hodgkin's disease.
    Stokoe CT; Ogden J; Jain VK
    Oncologist; 2001; 6(5):428-34. PubMed ID: 11675520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
    Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
    J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa.
    Zuze T; Ellis GK; Kasonkanji E; Kaimila B; Nyasosela R; Nyirenda R; Tomoka T; Mulenga M; Chikasema M; Tewete B; Mtangwanika A; Chiyoyola S; Chimzimu F; Kampani C; Mhango W; Nicholas S; Randall C; Montgomery ND; Fedoriw G; Westmoreland KD; Painschab MS; Gopal S
    Cancer Med; 2020 Jan; 9(1):77-83. PubMed ID: 31705618
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
    Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
    J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
    Haim N; Ben-Shahar M; Epelbaum R
    Cancer Chemother Pharmacol; 1995; 36(4):352-5. PubMed ID: 7543029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
    Wilson WH; Chabner BA; Bryant G; Bates S; Fojo A; Regis J; Jaffe ES; Steinberg SM; Goldspiel BR; Cheson BD
    J Clin Oncol; 1995 Feb; 13(2):381-6. PubMed ID: 7531220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study.
    Lamar ZS; Dothard A; Kennedy L; Isom S; Robinson M; Vaidya R; Hurd D; McClain D; Lesser G
    Leuk Lymphoma; 2018 Aug; 59(8):1871-1877. PubMed ID: 29252084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NHL-3 protocol. Six-drug combination chemotherapy for non-Hodgkin's lymphoma.
    Koziner B; Sklaroff R; Little C; Labriola D; Thaler HT; Straus DJ; Young CW; Nisce LZ; Oettgen H; Lee BJ
    Cancer; 1984 Jun; 53(12):2592-600. PubMed ID: 6547072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Alternating six-drug combination chemotherapy induction for intermediate and high-grade non-Hodgkin's lymphoma.
    Green JA; Errington RD; Nash JR; Coe MA; Warenius HM
    Cancer Chemother Pharmacol; 1989; 24(5):326-8. PubMed ID: 2758562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.